Diagnostic Performance of Noninvasive Imaging for Assessment of Axillary Response After Neoadjuvant Systemic Therapy in Clinically Node-positive Breast Cancer: A Systematic Review and Meta-analysis
- PMID: 33201095
- DOI: 10.1097/SLA.0000000000004356
Diagnostic Performance of Noninvasive Imaging for Assessment of Axillary Response After Neoadjuvant Systemic Therapy in Clinically Node-positive Breast Cancer: A Systematic Review and Meta-analysis
Abstract
Objective: The purpose of this study was to perform a systematic review and meta-analysis to determine the diagnostic performance of current noninvasive imaging modalities for assessment of axillary response after neoadjuvant systemic therapy (NST) in clinically node-positive breast cancer patients.
Summary of background data: NST can lead to downstaging of axillary lymph node disease. Imaging can potentially provide information about the axillary response to NST and, consequently, tailor the surgical management.
Methods: PubMed and Embase were searched for studies that compared noninvasive imaging after NST with axillary surgery outcome to identify axillary response in patients with initial pathologically proven axillary lymph node metastasis. Two reviewers independently screened the studies and extracted the data. A meta-analysis was performed by computing the pooled sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).
Results: Thirteen studies describing 2380 patients were included for final analysis. Of these patients, 1322 had undergone axillary ultrasound, 849 breast MRI, and 209 whole-body 18F-FDG PET-CT. The overall axillary pathologic complete response rate was 39.5% (941/2380). For axillary ultrasound, the pooled sensitivity, specificity, PPV, and NPV were 65%, 69%, 77%, 50%, respectively. For breast MRI, the pooled sensitivity, specificity, PPV, and NPV were 60%, 76%, 78%, 58%, respectively. For whole-body 18F-FDG PET-CT, the pooled sensitivity, specificity, PPV, and NPV were 38%, 86%, 78%, 49%, respectively.
Conclusions: The diagnostic performance of current noninvasive imaging modalities is limited to accurately assess axillary response after NST in clinically node-positive breast cancer patients.
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
The author reports no conflicts of interest.
Similar articles
-
Diagnostic performance of 18F-FDG PET/CT, ultrasonography and MRI. Detection of axillary lymph node metastasis in breast cancer patients.Nuklearmedizin. 2014;53(3):89-94. doi: 10.3413/Nukmed-0605-13-06. Epub 2013 Nov 13. Nuklearmedizin. 2014. PMID: 24220324
-
Comparison of the diagnostic value of FDG-PET/CT and axillary ultrasound for the detection of lymph node metastases in breast cancer patients.Acta Radiol. 2012 Dec 1;53(10):1092-8. doi: 10.1258/ar.2012.110635. Epub 2012 Sep 22. Acta Radiol. 2012. PMID: 23002144
-
Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.Acta Radiol. 2015 Aug;56(8):917-23. doi: 10.1177/0284185114539786. Epub 2014 Jul 10. Acta Radiol. 2015. PMID: 25013091
-
Diagnostic Accuracy of Different Surgical Procedures for Axillary Staging After Neoadjuvant Systemic Therapy in Node-positive Breast Cancer: A Systematic Review and Meta-analysis.Ann Surg. 2019 Mar;269(3):432-442. doi: 10.1097/SLA.0000000000003075. Ann Surg. 2019. PMID: 30312200 Free PMC article.
-
Axillary Pathologic Complete Response After Neoadjuvant Systemic Therapy by Breast Cancer Subtype in Patients With Initially Clinically Node-Positive Disease: A Systematic Review and Meta-analysis.JAMA Surg. 2021 Jun 1;156(6):e210891. doi: 10.1001/jamasurg.2021.0891. Epub 2021 Jun 9. JAMA Surg. 2021. PMID: 33881478 Free PMC article.
Cited by
-
Multiple-parameter MRI after neoadjuvant systemic therapy combining clinicopathologic features in evaluating axillary pathologic complete response in patients with clinically node-positive breast cancer.Br J Radiol. 2022 Oct 1;95(1139):20220533. doi: 10.1259/bjr.20220533. Epub 2022 Sep 19. Br J Radiol. 2022. PMID: 36000676 Free PMC article.
-
De-Escalation of Breast Cancer Surgery Following Neoadjuvant Systemic Therapy.Eur J Breast Health. 2021 Dec 30;18(1):6-12. doi: 10.4274/ejbh.galenos.2021.2021-5-4. eCollection 2022 Jan. Eur J Breast Health. 2021. PMID: 35059585 Free PMC article. Review.
-
Evaluating Magnetic Seed Localization in Targeted Axillary Dissection for Node-Positive Early Breast Cancer Patients Receiving Neoadjuvant Systemic Therapy: A Comprehensive Review and Pooled Analysis.J Clin Med. 2024 May 14;13(10):2908. doi: 10.3390/jcm13102908. J Clin Med. 2024. PMID: 38792449 Free PMC article. Review.
-
A comparative analysis of three graph neural network models for predicting axillary lymph node metastasis in early-stage breast cancer.Sci Rep. 2025 Apr 22;15(1):13918. doi: 10.1038/s41598-025-97257-z. Sci Rep. 2025. PMID: 40263507 Free PMC article.
-
Nomograms Integrating MRI-derived Apparent Diffusion Coefficient and Clinicopathologic Features for Prediction of Axillary Lymph Node Metastasis in Breast Cancer.Radiol Imaging Cancer. 2025 Mar;7(2):e240202. doi: 10.1148/rycan.240202. Radiol Imaging Cancer. 2025. PMID: 40116606 Free PMC article.
References
-
- Mougalian SS, Hernandez M, Lei X, et al. Ten-year outcomes of patients with breast cancer with cytologically confirmed axillary lymph node metastases and pathologic complete response after primary systemic chemotherapy. JAMA Oncol 2016; 2:508–516.
-
- Dominici LS, Negron Gonzalez VM, Buzdar AU, et al. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer 2010; 116:2884–2889.
-
- Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol 2016; 34:1072–1078.
-
- Donker M, Straver ME, Wesseling J, et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients the MARI procedure. Ann Surg 2015; 261:378–382.
-
- van Nijnatten TJA, Simons JM, Smidt ML, et al. A novel less-invasive approach for axillary staging after neoadjuvant chemotherapy in patients with axillary node-positive breast cancer by combining radioactive iodine seed localization in the axilla with the sentinel node procedure (RISAS): a Dutch prospective multicenter validation study. Clin Breast Cancer 2017; 17:399–402.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials